Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Akero Therapeutics, Inc. (AKRO : NSDQ)

• Company Description    Akero Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing transformational treatments for non-alcoholic steatohepatitis and other serious metabolic disorders. The company's product pipeline consists of AKR-001, for the treatment of non-alcoholic steatohepatitis, which are in clinical stage. Akero Therapeutics Inc. is based in San Francisco, United States. Number of Employees: 63

• Price / Volume Information    Yesterday's Closing Price: $52.00 Daily Weekly Monthly 20 Day Moving Average: 1,454,497 shares Shares Outstanding: 79.72 (millions) Market Capitalization: $4,145.31 (millions) Beta: -0.15 52 Week High: $58.40 52 Week Low: $21.34 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -2.91% -6.55% 12 Week 38.19% 16.23% Year To Date 86.92% 75.05%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 601 GATEWAY BOULEVARD SUITE 350 - SOUTH SAN FRANCISCO,CA 94080 USA ph: 650-487-6488 fax: - ir@akerotx.com http://www.akerotx.com

• General Corporate Information    Officers Andrew Cheng - Chief Executive Officer; President and Director William White - Executive Vice President; Chief Financial Officer Judy Chou - Director Seth L. Harrison - Director Jane P. Henderson - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00973Y108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/08/25 Share - Related Items Shares Outstanding: 79.72 Most Recent Split Date: (:1) Beta: -0.15 Market Capitalization: $4,145.31 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.97 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.96 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.82 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 200.00% vs. Previous Quarter: 190.91% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -15.19 12/31/24 - -32.23 ROA 06/30/25 - - 03/31/25 - -13.97 12/31/24 - -29.51 Current Ratio 06/30/25 - - 03/31/25 - 16.80 12/31/24 - 19.38 Quick Ratio 06/30/25 - - 03/31/25 - 16.80 12/31/24 - 19.38 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 13.60 12/31/24 - 10.75 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.03 12/31/24 - 0.05 Debt-to-Capital 06/30/25 - - 03/31/25 - 2.62 12/31/24 - 4.52

Powered by Zacks Investment Research ©